Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | muscleblind protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Brugia malayi | Muscleblind-like protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Echinococcus multilocularis | muscleblind protein 1 | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Echinococcus granulosus | muscleblind protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | glutamate receptor | 0.0335 | 0.7838 | 0.7838 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0304 | 0.6958 | 0.8878 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0281 | 0.6319 | 0.6929 |
Loa Loa (eye worm) | hypothetical protein | 0.0413 | 1 | 1 |
Loa Loa (eye worm) | metabotropic GABA-B receptor subtype 2 | 0.0086 | 0.088 | 0.088 |
Loa Loa (eye worm) | glutamate receptor | 0.0132 | 0.2162 | 0.2162 |
Brugia malayi | metabotropic glutamate receptor type 2 | 0.0163 | 0.3042 | 0.3881 |
Echinococcus multilocularis | muscleblind protein | 0.018 | 0.3518 | 0.3518 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 0.3518 | 0.3518 |
Brugia malayi | Muscleblind-like protein | 0.018 | 0.3518 | 0.4488 |
Echinococcus multilocularis | metabotropic glutamate receptor 2 | 0.0281 | 0.6319 | 0.6319 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.088 | 0.088 |
Onchocerca volvulus | Poor gastrulation protein homolog | 0.0054 | 0 | 0.5 |
Echinococcus multilocularis | muscleblind protein 1 | 0.018 | 0.3518 | 0.3518 |
Echinococcus granulosus | muscleblind protein | 0.018 | 0.3518 | 0.3518 |
Echinococcus granulosus | metabotropic glutamate receptor 2 | 0.0281 | 0.6319 | 0.6319 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0163 | 0.3042 | 0.3335 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0335 | 0.7838 | 1 |
Loa Loa (eye worm) | receptor family ligand binding region containing protein | 0.0086 | 0.088 | 0.088 |
Brugia malayi | Receptor family ligand binding region containing protein | 0.0086 | 0.088 | 0.1122 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0381 | 0.912 | 1 |
Onchocerca volvulus | Metabotropic glutamate receptor homolog | 0.0054 | 0 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0413 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 0.3518 | 0.3518 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | 0.1778 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 5.0119 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.